Review of studies on the use of microdosing with hallucinogens that combine psychotherapeutic techniques with administrations of LSD, MDMA or Psilocybin, as pharmacological complements in chronic psychopathologies, moderate, high, severe or chronic disorders, as well as in life-threatening diseases
Autor(a) principal: | |
---|---|
Data de Publicação: | 2023 |
Tipo de documento: | preprint |
Idioma: | spa |
Título da fonte: | SciELO Preprints |
Texto Completo: | https://preprints.scielo.org/index.php/scielo/preprint/view/6600 |
Resumo: | Microdosing (or microdoses) refers to ingesting a very low dose of a psychedelic substance, where there are no effects of cognitive, affective, perceptual and neurophysiological alterations. Institutions such as MAPS, Johns Hopkins University, Imperial College of London, and the FDA have recently designated such microdosing as a "breakthrough therapy" as it is a very promising alternative approach to mental health treatment. The purpose of this paper is to present a review of studies (double-blind, longitudinal, open, randomized and controlled trials [mostly with placebo]) on the use of microdosing with hallucinogens that combine psychotherapeutic techniques with administrations of LSD, MDMA or psilocybin, as pharmacological supplements in chronic psychopathologies, moderate, high, severe or chronic disorders, as well as in life-threatening diseases. Through, first, exposing the mechanisms of action of hallucinogens; second, explain the methodology for including relevant research in a period of fifteen years (2006-2021); third, show clinical trials; fourth and last, share a discussion about possible reported adverse effects. |
id |
SCI-1_267ee8d78905bf6ceedf20c9b675a92e |
---|---|
oai_identifier_str |
oai:ops.preprints.scielo.org:preprint/6600 |
network_acronym_str |
SCI-1 |
network_name_str |
SciELO Preprints |
repository_id_str |
|
spelling |
Review of studies on the use of microdosing with hallucinogens that combine psychotherapeutic techniques with administrations of LSD, MDMA or Psilocybin, as pharmacological complements in chronic psychopathologies, moderate, high, severe or chronic disorders, as well as in life-threatening diseasesRevisión sobre estudios del uso de microdosificación con alucinógenos que combinan técnicas psicoterapéuticas con administraciones de LSD, MDMA o Psilocibina, como complementos farmacológicos en psicopatologías crónicas, trastornos moderados, altos, graves o crónicos, así como en enfermedades potencialmente mortalesMicrodosingHallucinogensInnovative microdosing therapyLSDPsilocybinMDMAChronic psychopathologiesSevere disordersMicrodosificaciónAlucinógenosTerapia innovadora con microdosisMicrodosingLSDPsilocibinaMDMAPsicopatologías crónicasTrastornos gravesMicrodosing (or microdoses) refers to ingesting a very low dose of a psychedelic substance, where there are no effects of cognitive, affective, perceptual and neurophysiological alterations. Institutions such as MAPS, Johns Hopkins University, Imperial College of London, and the FDA have recently designated such microdosing as a "breakthrough therapy" as it is a very promising alternative approach to mental health treatment. The purpose of this paper is to present a review of studies (double-blind, longitudinal, open, randomized and controlled trials [mostly with placebo]) on the use of microdosing with hallucinogens that combine psychotherapeutic techniques with administrations of LSD, MDMA or psilocybin, as pharmacological supplements in chronic psychopathologies, moderate, high, severe or chronic disorders, as well as in life-threatening diseases. Through, first, exposing the mechanisms of action of hallucinogens; second, explain the methodology for including relevant research in a period of fifteen years (2006-2021); third, show clinical trials; fourth and last, share a discussion about possible reported adverse effects.La microdosificación (o las microdosis) hace referencia al ingerir una dosis muy baja de una sustancia psicodélica, donde no hay efectos de alteraciones cognitivas, afectivas, perceptivas y neurofisiológicas. Recientemente instituciones como la MAPS, la Universidad Johns Hopkins, el Imperial College of London y la FDA, a dicha microdosificación le han designado como «terapia innovadora», ya que es un enfoque alternativo muy prometedor para el tratamiento de salud mental.El propósito del presente es mostrar una revisión sobre estudios (a doble ciego, longitudinales, abiertos, ensayos aleatorizados y controlados [en su mayoría con placebo]) del uso de microdosificación con alucinógenos que combinan técnicas psicoterapéuticas con administraciones de LSD, MDMA o psilocibina, como complementos farmacológicos en psicopatologías crónicas, trastornos moderados, altos, graves o crónicos, así como en enfermedades máximamente mortales. A través, primero, de exponer los mecanismos de acción de los alucinógenos; segundo, explicar la metodología de inclusión de las investigaciones relevantes en un período de quince años (2006-2021); tercero, mostrar los clinicos; cuarto y último, compartir una discusión sobre posibles efectos adversos reportados.SciELO PreprintsSciELO PreprintsSciELO Preprints2023-09-01info:eu-repo/semantics/preprintinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://preprints.scielo.org/index.php/scielo/preprint/view/660010.1590/SciELOPreprints.6600spahttps://preprints.scielo.org/index.php/scielo/article/view/6600/12546Copyright (c) 2023 Aldo Chiquinihttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessChiquini, Aldoreponame:SciELO Preprintsinstname:Scientific Electronic Library Online (SCIELO)instacron:SCI2023-08-11T19:04:49Zoai:ops.preprints.scielo.org:preprint/6600Servidor de preprintshttps://preprints.scielo.org/index.php/scieloONGhttps://preprints.scielo.org/index.php/scielo/oaiscielo.submission@scielo.orgopendoar:2023-08-11T19:04:49SciELO Preprints - Scientific Electronic Library Online (SCIELO)false |
dc.title.none.fl_str_mv |
Review of studies on the use of microdosing with hallucinogens that combine psychotherapeutic techniques with administrations of LSD, MDMA or Psilocybin, as pharmacological complements in chronic psychopathologies, moderate, high, severe or chronic disorders, as well as in life-threatening diseases Revisión sobre estudios del uso de microdosificación con alucinógenos que combinan técnicas psicoterapéuticas con administraciones de LSD, MDMA o Psilocibina, como complementos farmacológicos en psicopatologías crónicas, trastornos moderados, altos, graves o crónicos, así como en enfermedades potencialmente mortales |
title |
Review of studies on the use of microdosing with hallucinogens that combine psychotherapeutic techniques with administrations of LSD, MDMA or Psilocybin, as pharmacological complements in chronic psychopathologies, moderate, high, severe or chronic disorders, as well as in life-threatening diseases |
spellingShingle |
Review of studies on the use of microdosing with hallucinogens that combine psychotherapeutic techniques with administrations of LSD, MDMA or Psilocybin, as pharmacological complements in chronic psychopathologies, moderate, high, severe or chronic disorders, as well as in life-threatening diseases Chiquini, Aldo Microdosing Hallucinogens Innovative microdosing therapy LSD Psilocybin MDMA Chronic psychopathologies Severe disorders Microdosificación Alucinógenos Terapia innovadora con microdosis Microdosing LSD Psilocibina MDMA Psicopatologías crónicas Trastornos graves |
title_short |
Review of studies on the use of microdosing with hallucinogens that combine psychotherapeutic techniques with administrations of LSD, MDMA or Psilocybin, as pharmacological complements in chronic psychopathologies, moderate, high, severe or chronic disorders, as well as in life-threatening diseases |
title_full |
Review of studies on the use of microdosing with hallucinogens that combine psychotherapeutic techniques with administrations of LSD, MDMA or Psilocybin, as pharmacological complements in chronic psychopathologies, moderate, high, severe or chronic disorders, as well as in life-threatening diseases |
title_fullStr |
Review of studies on the use of microdosing with hallucinogens that combine psychotherapeutic techniques with administrations of LSD, MDMA or Psilocybin, as pharmacological complements in chronic psychopathologies, moderate, high, severe or chronic disorders, as well as in life-threatening diseases |
title_full_unstemmed |
Review of studies on the use of microdosing with hallucinogens that combine psychotherapeutic techniques with administrations of LSD, MDMA or Psilocybin, as pharmacological complements in chronic psychopathologies, moderate, high, severe or chronic disorders, as well as in life-threatening diseases |
title_sort |
Review of studies on the use of microdosing with hallucinogens that combine psychotherapeutic techniques with administrations of LSD, MDMA or Psilocybin, as pharmacological complements in chronic psychopathologies, moderate, high, severe or chronic disorders, as well as in life-threatening diseases |
author |
Chiquini, Aldo |
author_facet |
Chiquini, Aldo |
author_role |
author |
dc.contributor.author.fl_str_mv |
Chiquini, Aldo |
dc.subject.por.fl_str_mv |
Microdosing Hallucinogens Innovative microdosing therapy LSD Psilocybin MDMA Chronic psychopathologies Severe disorders Microdosificación Alucinógenos Terapia innovadora con microdosis Microdosing LSD Psilocibina MDMA Psicopatologías crónicas Trastornos graves |
topic |
Microdosing Hallucinogens Innovative microdosing therapy LSD Psilocybin MDMA Chronic psychopathologies Severe disorders Microdosificación Alucinógenos Terapia innovadora con microdosis Microdosing LSD Psilocibina MDMA Psicopatologías crónicas Trastornos graves |
description |
Microdosing (or microdoses) refers to ingesting a very low dose of a psychedelic substance, where there are no effects of cognitive, affective, perceptual and neurophysiological alterations. Institutions such as MAPS, Johns Hopkins University, Imperial College of London, and the FDA have recently designated such microdosing as a "breakthrough therapy" as it is a very promising alternative approach to mental health treatment. The purpose of this paper is to present a review of studies (double-blind, longitudinal, open, randomized and controlled trials [mostly with placebo]) on the use of microdosing with hallucinogens that combine psychotherapeutic techniques with administrations of LSD, MDMA or psilocybin, as pharmacological supplements in chronic psychopathologies, moderate, high, severe or chronic disorders, as well as in life-threatening diseases. Through, first, exposing the mechanisms of action of hallucinogens; second, explain the methodology for including relevant research in a period of fifteen years (2006-2021); third, show clinical trials; fourth and last, share a discussion about possible reported adverse effects. |
publishDate |
2023 |
dc.date.none.fl_str_mv |
2023-09-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/preprint info:eu-repo/semantics/publishedVersion |
format |
preprint |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://preprints.scielo.org/index.php/scielo/preprint/view/6600 10.1590/SciELOPreprints.6600 |
url |
https://preprints.scielo.org/index.php/scielo/preprint/view/6600 |
identifier_str_mv |
10.1590/SciELOPreprints.6600 |
dc.language.iso.fl_str_mv |
spa |
language |
spa |
dc.relation.none.fl_str_mv |
https://preprints.scielo.org/index.php/scielo/article/view/6600/12546 |
dc.rights.driver.fl_str_mv |
Copyright (c) 2023 Aldo Chiquini https://creativecommons.org/licenses/by/4.0 info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Copyright (c) 2023 Aldo Chiquini https://creativecommons.org/licenses/by/4.0 |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
SciELO Preprints SciELO Preprints SciELO Preprints |
publisher.none.fl_str_mv |
SciELO Preprints SciELO Preprints SciELO Preprints |
dc.source.none.fl_str_mv |
reponame:SciELO Preprints instname:Scientific Electronic Library Online (SCIELO) instacron:SCI |
instname_str |
Scientific Electronic Library Online (SCIELO) |
instacron_str |
SCI |
institution |
SCI |
reponame_str |
SciELO Preprints |
collection |
SciELO Preprints |
repository.name.fl_str_mv |
SciELO Preprints - Scientific Electronic Library Online (SCIELO) |
repository.mail.fl_str_mv |
scielo.submission@scielo.org |
_version_ |
1797047812433641472 |